A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant

Delayed Function of Renal Transplant Clinical Trial

Official title:

Pilot Study of the Clinical Activity of Eculizumab for Prevention of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01403389
• Other study ID #: HSM 10-1600
• Status: Terminated
• Phase: Phase 2
• Start date: December 1, 2011
• Est. completion date: February 6, 2014

Study information

• Verified date: May 2019
• Source: Schroppel, Bernd, M.D.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if Eculizumab is safe and effective in the prevention of delayed graft function following deceased donor kidney transplantation.

Description:

Based on experimental data and supportive observations in humans associating complement gene upregulation with ischemic reperfusion injury, it is hypothesized that C5 cleavage is a key step in the pathogenesis of ischemic reperfusion injury following transplantation. It is further hypothesized that eculizumab, an antibody that blocks C5 cleavage in humans will be an effective prophylactic agent to prevent ischemic reperfusion injury in high risk recipients. To test this hypothesis, this study is a pilot prospective, randomized study to test the efficacy of eculizumab vs. placebo given once at the time of transplantation in preventing delayed graft function in first adult recipients of deceased donor kidneys.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: February 6, 2014
• Est. primary completion date: August 6, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 or older

• Weight > 40 kg

• Male or Female

• Recipients of first deceased donor kidneys

• Able to provide written informed consent

• Transplant candidate as per site specific guidelines

• Dialysis dependent renal failure (initiated more than 2 months prior to transplant)

• Novartis Delayed Graft Function Score 3-8

• Extended criteria donor with brain death, or standard criteria donor with cold ischemic time < 24 hours

Exclusion Criteria:

• Planned to receive multi-organ transplant

• Kidneys from donors < 6 years of age

• Dual kidney transplant (from same donor, including en bloc)

• Living donor kidney

• Highly sensitized recipients (PRA > 50%)

• Previous transplant

• Participation in another investigational trial

• Recipient BMI > 40

• ABO incompatible

• DCD Donor

• Preemptive kidney transplant

• Recipients with DGF scores < 3 or > 8

• Women who are pregnant or breast feeding

• Women of child bearing potential who are unable or unwilling to use a medically acceptable form of contraception

• Patients infected with HIV, HCV or HBV

• Active bacterial or other infection which is clinically significant in the opinion of the investigator

• Patients with history of splenectomy

• Patients with history of meningococcal disease

• Patients with known or suspected hereditary complement deficiency

• Patients with history of cancer (other than non-melanoma skin cancers) within the last 5 years

Related Conditions & MeSH terms

• Delayed Function of Renal Transplant
• Delayed Graft Function

Intervention

Drug:
• Eculizumab
1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion
• Placebo
240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion

Locations

Country	Name	City	State
United States	Mount Sinai Recanati/Miller Transplantation Institute	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Schroppel, Bernd, M.D.	Alexion Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite of Delayed Graft Function and Slow Graft Function	Delayed Graft Function defined as follows: A need for at least one dialysis treatment during the first 7 days after transplantation (not including a single session for hyperkalemia or hypervolemia in the first 48 hours); A less than or equal to 50% reduction in serum creatinine in the first 24 hours post-transplantation; A serum creatinine reduction ratio < 30% at 48 hours post-transplantation; Slow Graft Function Defined as Follows: A functioning graft at Day 5 Post-transplantation with a serum creatinine > 3 mg/dL and no need for dialysis	Up to 6 months